ETON
Eton Pharmaceuticals Cements its Position as a Leader in Rare Diseases with Record-Breaking Q4 2025 Results
Eton Pharmaceuticals made waves in the rare disease space with its fourth quarter 2025 financial results, capping off an outstanding year of growth and transformation. The company's strong revenue performance was driven by the successful launch of three new products: Increlex, Galzin, and KHINDIVI. The addition of these